Charles Schwab Investment Management Inc. Grows Stock Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK)

Charles Schwab Investment Management Inc. lifted its position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) by 55.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,459 shares of the company’s stock after acquiring an additional 18,287 shares during the period. Charles Schwab Investment Management Inc. owned 0.22% of Outlook Therapeutics worth $275,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in OTLK. Great Point Partners LLC boosted its stake in Outlook Therapeutics by 15.0% during the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after purchasing an additional 221,510 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Outlook Therapeutics in the second quarter worth about $232,000. AQR Capital Management LLC acquired a new position in Outlook Therapeutics during the second quarter worth about $75,000. Susquehanna Fundamental Investments LLC purchased a new stake in Outlook Therapeutics during the 2nd quarter valued at about $303,000. Finally, Christensen King & Associates Investment Services Inc. purchased a new stake in Outlook Therapeutics during the 3rd quarter valued at about $55,000. 11.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on OTLK. BTIG Research lowered their target price on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Ascendiant Capital Markets lowered their price objective on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Outlook Therapeutics in a report on Friday, November 29th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Outlook Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $42.34.

Insider Buying and Selling

In related news, CFO Lawrence A. Kenyon bought 5,000 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were bought at an average price of $5.69 per share, with a total value of $28,450.00. Following the completion of the transaction, the chief financial officer now directly owns 5,946 shares of the company’s stock, valued at $33,832.74. This represents a 528.54 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.40% of the company’s stock.

Outlook Therapeutics Stock Down 0.7 %

NASDAQ:OTLK opened at $1.39 on Friday. Outlook Therapeutics, Inc. has a 52 week low of $0.87 and a 52 week high of $12.85. The stock’s fifty day moving average is $4.24 and its two-hundred day moving average is $6.13. The company has a market capitalization of $32.88 million, a P/E ratio of -0.13 and a beta of 0.46.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.